Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib

Leukemia. 2015 Feb;29(2):498-500. doi: 10.1038/leu.2014.286. Epub 2014 Sep 25.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Benzamides / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Female
  • Follow-Up Studies
  • Humans
  • Janus Kinase 2 / immunology
  • Male
  • Middle Aged
  • Nitriles
  • Primary Myelofibrosis / immunology
  • Primary Myelofibrosis / therapy*
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Remission Induction
  • Treatment Outcome

Substances

  • Benzamides
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
  • ruxolitinib
  • JAK2 protein, human
  • Janus Kinase 2